Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Medarex Gains Novo Nordisk Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Medarex Gains Novo Nordisk Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Medarex, Inc. will receive a milestone payment for an undisclosed amount from its licensing partner, Novo Nordisk A/S. The payment is a result of the submission of an IND by Novo Nordisk for the clinical development of an antibody generated by Medarex’s UltiMAb technology. Medarex may receive future milestone payments and royalties should the product candidate progress through clinical development and to the market.

“We are pleased with the milestone achieved by Novo Nordisk and look forward to continued development progress with this antibody,” said Howard H. Pien, president and chief executive officer of Medarex. “Product development advances of this type by Novo Nordisk and our other partners underpin the important role of our antibody technology in the development of new therapeutics.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters